All In MedTech

FDA Clearance Tracker · K243866

InVision Precision Cardiac Amyloid

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this decision)Source: openFDAMethods & limitations

510(k)Breakthrough

Decided

May 21, 2025

Substantially Equivalent

Time to decision

155 days

Received Dec 17, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K243866
Device name
InVision Precision Cardiac Amyloid
Applicant location
Los Angeles, CA
Received
Dec 17, 2024
Decided
May 21, 2025
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 870.2200
Specialty
Cardiology

Every decision under product code SDJ

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code SDJ. The earliest in FDA's data is K240860, decided Nov 15, 2024.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for InVision Medical Technology Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.